ReproNovo products

With our lead product candidate, RPN-001 (leflutrozole), the focus of our clinical research is on treating infertile men with low serum testosterone. RPN-001 is a novel molecular entity with the potential to enhance spermatogenesis. By inhibiting the aromatase enzyme, leflutrozole suppresses the conversion of testosterone to estradiol, thereby normalizing testosterone levels and rebalancing the testosterone to estradiol ratio. Additionally, it stimulates the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These effects lead to improved testicular function and increased spermatogenesis.

Our second asset RPN-002 (nolasiban) is an oxytocin receptor antagonist. RPN-002 has the potential to increase pregnancy rates and live birth rates in women undergoing embryo transfer after IVF. Clinical studies have demonstrated that blocking oxytocin receptor activation can decrease uterine contractions, increase blood flow to the lining of the uterus and help it better prepare for pregnancy by enhancing its ability to support embryo implantation.